Date & Time of Session - 11/17/25 - from 12:00 - 1:00 PM

Needs/Overview
The escalating threat of antimicrobial resistance (AMR), particularly from multidrug-resistant (MDR) P. aeruginosa, demands continuous mastery of our newest therapeutic options. Given the increase in hospital utilization of agents such as Zerbaxa and Avycaz, it is imperative that all pharmacists are proficient in the rationale and appropriate use of these crucial antibiotics. This Grand Rounds presentation is designed to address this educational need by providing a robust, evidence-based platform for pharmacists practicing across the full continuum of care. We will meticulously review the mechanisms of resistance that these drugs overcome, thereby justifying their specific use against challenging strains. Crucially, the presentation will provide an in-depth analysis of the key approval trials and current clinical guidelines for treating complicated MDR P. aeruginosa infections. Pharmacists will leave with a clear understanding of when and how to integrate these agents into patient care, thus minimizing resistance development. Ultimately, this session will enhance the pharmacist's role in delivering high-level antimicrobial stewardship and ensuring optimal, consistent patient care.

Objectives
Upon completion of this activity, participants will be able to:
1. Identify key resistance mechanisms in Pseudomonas aeruginosa 
2. Evaluate current treatment options and their limitations 
3. Apply guideline recommendations to current clinical practice
4. Recommend appropriate therapeutic alternatives based on resistance patterns

Target Audience
Free 1 credit hour of Continuing Education for St Elizabeth Health Care providers, Pharmacists, Residents and Students

Special Services
If you require special assistance to attend this event, please call Deanna Fliehman at (859) 301-6191

Speaker
Daphne Boggs, PharmD
PGY1 Pharmacy Resident
St Elizabeth Healthcare - Edgewood, Kentucky